ProMIS™ Neurosciences, Inc.

This company is a biotech company that discovers and develops accuracy therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative disease especially Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia. Moreover, this company has exclusive access to critical IP and proprietary know-how in the area. The Company’s patent estate consists of eight patent families issued or pending. ProMIS™ Neurosciences, Inc. utilizes its computational discovery platform, ProMIS™, to predict novel aims known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.